Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516358 | 0.95 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL12903278 | 0.95 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL334794 | 0.95 | MEN1 (0.62) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL8478562 | 0.93 | MEN1 (0.60) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL31549217 | 0.93 | MEN1 (0.60) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL334304 | 0.89 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL2186409 | 0.89 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL2186406 | 0.89 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL29606950 | 0.89 | MEN1 (0.68) | MEN1KMT2ATSHRTAAR1LMNA | |
| SCHEMBL19559214 | 0.88 | MEN1 (0.50) | MEN1KMT2ATSHRTAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2022-05-05 | — | — | US | disclosed |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2022-05-05 | — | — | US | disclosed |
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2018-08-09 | — | — | US | disclosed |
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2018-08-09 | — | — | US | disclosed |
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | Temple University--of the Commonwealth System of Higher Education | 2018-08-09 | — | — | US | disclosed |
| WO-2016183150-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016183150-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-11-17 | — | — | WO | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-4021454-A | ALLYL CHLORIDE, HYDROCARBON HYDROPEROXIDE IN SILICON, TANTALUM OXIDE-HYDROXIDE | SHELL OIL COMPANY (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221365-A1 | NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | MEN1 4868/4885KMT2A 2787/4885TSHR 354/4885 |
| US-20220133713-A1 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE | SIGMAR1, TMEM97, OPRL1 | MEN1 4844/4885KMT2A 2208/4885TSHR 323/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | MEN1 2456/4885KMT2A 939/4885TSHR 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.